Fusion Pharmaceuticals — Merger or Acquisition (February 2023)
27 slides from Fusion Pharmaceuticals's merger presentation, Feb 13, 2023
Slide 1: Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved February 13, 2023 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Fusion Pharmaceuticals, Inc. (“we,” “us,” “our,” “Fusion” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not h
Slide 3: Summary
Summary Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved Clinical data is emerging showing superior efficacy1 with alpha therapies vs beta in mCRPC (e.g. 177Lu-PSMA vs. 225Ac-PSMA) Creates opportunities to be a best-in-class therapy for Lu naive and treat relapsed/refractory patients
Slide 4: PSMA Radiopharmaceuticals: Current Developments, Challenges and Opportunities
PSMA Radiopharmaceuticals: Current Developments, Challenges and Opportunities Oliver Sartor, MD Laborde Professor of Cancer Research Medical Director Tulane Cancer Center Departments of Medicine and Urology Associate Dean for Oncology Tulane Medical School New Orleans, Louisiana
Slide 5: Introduction: PSMA Radiotherapies Clinical Trial Summary
Introduction O’Driscott C et al, Br J Pharm 2016 Agent / Type Sponsor Isotope Ongoing Trials Phase Beta Alpha J591 Cornell 177Lu I/II* Antibody J591 Cornell 225Ac I* TLX591 Telix 177Lu I PSMA TTC Bayer 227Th I PSMA I&T POINT 177Lu III Small Molecule PSMA I&T Curium 177Lu III PSMA-617 Novartis 177Lu
Slide 6: PSMA-Targeted Radiotherapies: Betas and Alphas
PSMA-Targeted Radiotherapies: Betas and Alphas Current PSMA radiotherapies rely on two radiations: Beta: Single stranded DNA breakage possessing lower linear energy transfer with deeper penetration Alpha radiation: Double stranded DNA breakage possessing a high energy transfer with short penetration
Slide 7: PSMA-Targeted Radiotherapies: Betas lay the foundation
PSMA-Targeted Radiotherapies: Betas lay the foundation The phase III VISION study with (177Lu)-PSMA-617 represented a pivotal step forward to radiopharmaceuticals resulting in FDA approval in advanced metastatic castrate-resistant prostate cancer (mCRPC) OS: HR 0.62 (95% CI 0.52-0.74) Number still a
Slide 8: Betas Are Now an Important Part of the Treatment Paradigm
Betas Are Now an Important Part of the Treatment Paradigm New unmet need exists for post-PLUVICTO® patients What do we do when patients still progress?
Slide 9: PSMA-Targeted Radiotherapies: From Betas to Alphas
Kratochwil et a. J Nuc Med 57: 1-4, 2016 PSMA-Targeted Radiotherapies: From Betas to Alphas PSMA targeted alpha emitters (Actinium-225) as 9th line treatment
Slide 10: Activity of Alpha (Actinium-225) Post-Beta (Lutetium-177) Failure
Kratochwil et a. J Nuc Med 57: 1-4, 2016 PSMA-Targeted Radiotherapies: From Betas to Alphas Activity of Alpha (Actinium-225) Post-Beta (Lutetium-177) Failure
Slide 11: Overview of select investigator studies
Overview of select investigator studies
Slide 12: Summary
Summary PSMA represents a validated target for prostate cancer therapeutics The Phase III VISION study with 177lutetium (177Lu)-PSMA-617 represented a pivotal step forward and the FDA has now approved this agent in advanced metastatic castrate-resistant prostate cancer (mCRPC) Patients progressing a
Slide 13: Established Roadmap for PSMA-Targeted Radioligand Therapies (RLTs)
Established Roadmap for PSMA-Targeted Radioligand Therapies (RLTs) 2017 2018 2019 2020 2021 2022 Sources: company press releases, ClinicalTrials.gov; 1) GlobalData Prostate Cancer Market Forecast 2018-2028 (updated Oct 2022) Established roadmap for being the first to market in a growing sector *Fusi
Slide 14: Alpha emitters are emerging as the next generation of PSMA RLTs
Alpha emitters are emerging as the next generation of PSMA RLTs – potential to be more potent and precise than betas Alpha particles (e.g., 225Ac) deliver 1,500 times more linear energy transfer (LET) than beta emitters (e.g., 177Lu) 60-100 vs 0.1-1 keV/m Energy delivered over a short distance to se
Slide 15: Multiple investigator sponsored studies support potential of 225Ac-PSMA
2x 177Lu 1x 225Ac 1x 225Ac 2x 177Lu 2 x 225Ac 2x 177Lu Multiple investigator sponsored studies support potential of 225Ac-PSMA Over 250 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA Compelling efficacy data 177Lu-naïve: 63-66% biochemical response rates Post–177Lu: 28-65%
Slide 16: Fusion is well positioned to bring the first 225Ac-PSMA agent to market
Fusion is well positioned to bring the first 225Ac-PSMA agent to market from supply chain and alpha experience perspectives Largest dedicated TAT manufacturing facility globally Internal GMP manufacturing to be fully operational by 2024 Clinical & commercial supply capabilities Adjacent to current R
Slide 17: Current landscape of actinium PSMA programs
Current landscape of actinium PSMA programs Sources: GlobalData, Company websites, ClinicalTrials.gov 225Ac-PSMA programs Others [225Ac]-PSMA-617* [225Ac]-J591 (Ph1/2) [225Ac]-PSMA-I&T *ex-US only Company/Study Phase 1 Phase 2 Phase 3 Preclinical Marketed Bulk of other PSMA development is with beta
Slide 18: TATCIST Trial Summary
Patient population (mCRPC) Progressive disease, with docetaxel/cabazitaxel or declined taxane therapy by the patient With or without prior 177Lu-PSMA treatment Positive 68Ga-PSMA-11 PET/CT defined as SUV ≥2.0 Phase 2 study design n=100; Number of cycles per patient = 4 Dosing every 8 weeks Starting
Slide 19: Multiple investigator sponsored studies support potential of 225Ac-PSMA
2x 177Lu 1x 225Ac 1x 225Ac 2x 177Lu 2 x 225Ac 2x 177Lu Multiple investigator sponsored studies support potential of 225Ac-PSMA Over 250 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA Compelling efficacy data 177Lu-naïve: 63-66% biochemical response rates Post–177Lu: 28-65%
Slide 20: Preliminary data from TATCIST
Preliminary data from TATCIST (updated as of January 29th ) 10 177Lu-naïve patients enrolled PSA50 response 4/10 (40%) at any time 4/8 (50%) at Week 8 (after 1 cycle) Preliminary TATCIST data is consistent with published data on 225Ac-PSMA; xerostomia has been manageable Note: evaluable patients bas
Slide 21: Results consistent with expectations based upon study population
Results consistent with expectations based upon study population Summary: Increase in PSA has been observed in certain patients in the study prior to 8-week post-treatment target efficacy assessment date Two of these patients had ECOG Performance Status 2, a well-known adverse prognostic factor (sig
Slide 22: Development strategy
Development strategy Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved In ~12 months Fusion will be able to report: Notes: Endocyte (acq. By Novartis) had data on just 30 patients from an IIT Ph2 trial before they commenced Ph3; POINT leveraged data from 27 patients from their lead-in
Slide 23: Significant and growing unmet need amongst 177Lu-relapsed/refractory patients
Significant and growing unmet need amongst 177Lu-relapsed/refractory (177Lu-R/R) patients Unmet Need Today (w/ just VISION data/approval) Potential in 2-3 yrs (w/ VISION + PSMAfore + PSMAddition data/approvals) 177Lu-PSMA use (post-taxane) Hormone-sensitive (HSPC) Castration-resistance (CRPC) Castra
Slide 24: Strong team positioned to execute
Strong team positioned to execute Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved Expanded R&D team with deep PSMA, radiopharmaceutical and oncology experience Clinical Operations expertise from VISION trial Scientific co-founder of Endocyte (Pluvicto developer acq. by Novartis) Onc
Slide 25: Multiple layers of protection for Fusion's first mover advantage
Multiple layers of protection for Fusion’s first mover advantage 177Lu-PSMA I&T was published & not patented Clinical data look similar to Pluvicto Freedom to operate to be pursued via robust IPR to be filed to invalidate a broad patent that covers multiple 225Ac-PSMA agents1 Potential for five year
Slide 26: 225Ac-PSMA-I&T adds to Fusion's strong pipeline
225Ac-PSMA-I&T adds to Fusion’s strong pipeline Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved With one Phase 2 (PSMA) program, three ongoing Phase 1 programs, and a near-term IND expected via our AZ collaboration, we expect to have multiple clinical updates over the next 6-24 mont
Slide 27: Fusion uniquely positioned to be first-to-market with 225Ac-PSMA
Fusion uniquely positioned to be first-to-market with 225Ac-PSMA Copyright © 2023 Fusion Pharmaceuticals Inc. All Rights Reserved Unmet Need Potential 1st to Market PSMA PET scans of a mCRPC patient treated with two cycles of 225Ac-PSMA-I&T in the TATCIST trial. A CR where the PSA level decreased fr
Fusion Pharmaceuticals — Merger or Acquisition (February 2023) on 6ix